Prot #OMS-I103: The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressin

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/20 → 7/1/23

Funding

  • Precision Oncology, LLC (Prot #OMS-I103)
  • OncoSec Medical Incorporated (Prot #OMS-I103)